# OnCo record trastuzumab-biosimilars (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/trastuzumab-biosimilars/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "trastuzumab-biosimilars" ;
  schema:name "Trastuzumab biosimilars"@en ;
  schema:description "Near-identical copies of Herceptin, approved since 2017, that cut the price of HER2 treatment and widened access worldwide."@en ;
  schema:url <https://onco.cc/drugs/trastuzumab-biosimilars/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Biosimilar> ;
  owl:sameAs <http://www.wikidata.org/entity/Q864715> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20biosimilars> ;
  onco:status "approved" ;
  onco:modality "Biosimilar monoclonal antibody (anti-HER2)" ;
  schema:alternateName "Ogivri, Herzuma, Kanjinti, Trazimera, Ontruzant, Hercessi" ;
  onco:approval "US 2017: First trastuzumab biosimilar (Ogivri); all trastuzumab indications", "EU 2017: Ontruzant, first EU trastuzumab biosimilar" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/gastric/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/organon/> ;
  onco:terms <https://onco.cc/terms/biosimilar/> ;
  onco:trials <https://onco.cc/trials/nct01275677/>, <https://onco.cc/trials/nct00769379/>, <https://onco.cc/trials/nct02003209/> .